Neurocognitive effectiveness of quetiapine, olanzapine, risperidone, and ziprasidone: A pragmatic, randomized trial

European Psychiatry

Volumn 28, Issue 3, 2013, Pages 174-184

  Johnsen, E ^a,b   Jorgensen H A ^b   Kroken, R A ^a,c   Loberg E M ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c Inst Biological and Medical Psychology ^*  (Norway)

Author keywords

Antipsychotics; Cognitive symptoms; Psychoses; Randomized controlled trial

Indexed keywords

OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

EID: 84875072629     PISSN: 09249338     EISSN: 17783585     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2011.10.003     Document Type: Article

References (43)

1. Bilder R.M., Goldman R.S., Volavka J., Czobor P., Hoptman M., Sheitman B., et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002, 159:1018-1028.
2. Campbell N., Boustani M., Limbil T., Ott C., Fox C., Maidment I., et al. The cognitive impact of anticholinergics: a clinical review. Clin Interv Aging 2009, 4:2252-2333.
3. Cuesta M.J., de Jalón E.G., Campos M.S., Peralta V. Cognitive effectiveness of olanzapine and risperidone in first-episode psychosis. Br J Psychiatry 2009, 194:439-445.
4. Davidson M., Galderisi S., Weiser M., Werbeloff N., Fleischhacker W.W., Keefe R.S., et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry 2009, 166:675-682.
5. Davis J.M. Dose equivalence of the antipsychotic drugs. J Psychiatr Res 1974, 11:65-69.
6. Dominguez M., de G., Viechtbauer W., Simons C.J., van Os J., Krabbendam L. Are psychotic psychopathology and neurocognition orthogonal? A systematic review of their associations. Psychol Bull 2009, 135:157-171.
7. Drake R.E., Rosenberg S.D., Mueser K.T. Assessing substance use disorder in persons with severe mental illness. New Dir Health Serv 1996, 70:3-17.
8. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia. Am J Psychiatry 1996, 153:321-330.
9. Gray J.A., Roth B.L. Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr Bull 2007, 33:1100-1119.
10. Harvey P.D., Patterson T.L., Potter L.S., Zhong K., Brecher M. Improvement in social competence with short-term atypical antipsychotic treatment: a randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning. Am J Psychiatry 2006, 163:1918-1925.
11. Harvey P.D., Sacchetti E., Galluzzo A., Romeo F., Gorini B., Bilder R.M., et al. A randomized double-blind comparison of ziprasidone vs. clozapine for cognition in patients with schizophrenia selected for resistance or intolerance to previous treatment. Schizophr Res 2008, 105:138-143.
12. Harvey P.D., Bowie C.R., Loebel A. Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a six-month randomized, double-blind comparison of ziprasidone vs. olanzapine. J Neuropsychiatry Clin Neurosci 2006, 18:54-63.
13. Heaton R.K., Gladsjo J.A., Palmer B.W., Kuck J., Marcotte T.D., Jeste D.V. Stability and course of neuropsychological deficits in schizophrenia. Arch Gen Psychiatry 2001, 58:24-32.
14. Heaton RK, Grant I, Matthews CG. Comprehensive norms for an expanded Halstead-Reitan battery. Demographic corrections, research findings, and clinical applications. Psychological assessment resources 1991, Odessa, Florida, USA.
15. Hedden S.L., Woolson R.F., Carter R.E., Palesch Y., Ypadhyaya H.P., Malcolm R.J. The impact of loss to follow-up on hypothesis tests of the treatment effect for several statistical methods in substance abuse trials. J Subst Abuse Treat 2009, 37:54-63.
16. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions 4.2.6. ; 2006 [accessed 23rd April 2009]. http://www.cochrane.org/resources/handbook/hbook.htm.
17. Hill S.K., Reilly J.L., Harris M.S.H., Rosen C., Marvin R.W., Deleon O., et al. A comparison of neuropsychological dysfunction in first-episode psychosis patients with unipolar depression, bipolar disorder, and schizophrenia. Schizophr Res 2009, 113(a):167-175.
18. Johnsen E., Kroken R.A., Wentzel-Larsen T., Jørgensen H.A. Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone. BMC Psychiatry 2010, 10:26.
19. Kahn R., Fleischhacker W.W., Boter H., Davidson M., Vergouwe Y., Keet I.P.M., et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial. Lancet 2008, 371:1085-1097.
20. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
21. Keefe R.S.E., Bilder R.M., Davis S.M., Harvey P.D., Palmer B.W., Gold J.M., et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry 2007, 64:633-647.
22. Keefe R.S.E., Fox K.H., Harvey P.D., Cucchiaro J., Siu C., Loebel A. Characteristics of the MATRICS consensus cognitive battery in a 29-site antipsychotic schizophrenia clinical trial. Schizophr Res 2011, 125:161-168.
23. Keefe R.S.E., Sweeney J.A., Gu H., Hamer R.M., Perkins D.O., McEvoy J.P., et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007, 164:1061-1071.
24. Leucht S., Heres S., Hamann J., Kane J.M. Methodological issues in current antipsychotic drug trials. Schizophr Bull 2008, 34:275-285.
25. Løberg EM, Langeland M, Jørgensen HA. Reliability and validity of a Norwegian translation of the repeatable battery for the assessment of neuropsychological status in patients with psychosis. 10 year anniversary of the Norwegian neuropsychological association 2006 [Abstract].
26. March J.S., Silva S.G., Compton S., Shapiro M., Califf R., Krishnan R. The case for practical clinical trials in psychiatry. Am J Psychiatry 2005, 162:836-846.
27. Marder S.R. Lessons from MATRICS. Schizophr Bull 2011, 37:233-234.
28. Palmer B.W., Dawes S.E., Heaton R.K. What do we know about neuropsychological aspects of schizophrenia?. Neuropsychol Rev 2009, 19:365-384.
29. Pinheiro C., Bates D.M. Mixed effects models in S and S-plus 2000, Springer, New York.
30. R Development Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria 2008. ISBN 3-900051-07-0. [accessed November 02, 2008]. http://www.r-project.org/.
31. Randolph C., Tierney M.C., Mohr E., Chase T.N. The repeatable battery for the assessment of neuropsychological status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol 1998, 20:310-319.
32. Riedel M., Schennach-Wolff R., Musil R., Dehning S., Cerovecki A., Opgen-Rhein M., et al. Spellmann. Neurocognition and its influencing factors in the treatment of schizophrenia - effects of aripiprazole, olanzapine, quetiapine, and risperidone. Hum Psychopharmacol Clin Exp 2010, 25:116-125.
33. Riedel M., Müller N., Spellmann I., Engel R.R., Musil R., Valdevit R., et al. Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia. Eur Arch Psychiatry Clin Neurosci 2007, 257:402-412.
34. Riedel M., Spellmann I., Strassnig M., Douhet A., Dehning S., Opgen-Rhein M., et al. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms. Eur Arch Psychiatry Clin Neurosci 2007, 257:360-370.
35. Robles O., Zabala A., Bombín I., Parellada M., Moreno D., Ruiz-Sancho A., et al. Cognitive efficacy of quetiapine and olanzapine in early-onset first-episode psychosis. Schizophr Bull 2011, 37:405-415.
36. Ronning M. The WHO collaborating centre for drug statistics methodology. Established 1982, [accessed November 02, 2008]. http://www.whocc.no/atcddd/.
37. Smith M.J., Barch D.M., Csernansky J.G. Bridging the gap between schizophrenia and psychotic mood disorders: relating neurocognitive deficits to psychopathology. Schizophr Res 2009, 107:69-75.
38. Tandon R., Belmaker R.H., Gattaz W.F., Lopez-Ibor J.J., Okasha A., Singh B., et al. Section of pharmacopsychiatry. World psychiatric association. World psychiatric association pharmacopsychiatry section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res 2008, 100:20-38.
39. Van Veelen N.M.J., Grootens K.P., Peuskens J., Sabbe B.G., Salden M.E., Verkes R.J., et al. Short term neurocognitive effects of treatment with ziprasidone and olanzapine in recent onset schizophrenia. Schizophr Res 2010, 120:191-198.
40. Voruganti L.P., Awad A.G., Parker G., Forrest C., Usmani Y., Fernando M.L., et al. Cognition, functioning and quality of life in schizophrenia treatment: results of a one-year randomized controlled trial of olanzapine and quetiapine. Schizophr Res 2007, 96:146-155.
41. Wilk C.M., Gold J.M., Bartko J.J., Dickerson F., Fenton W.S., Knable M., et al. Test-retest stability of the repeatable battery for the assessment of neuropsychological status in schizophrenia. Am J Psychiatry 2002, 159:838-844.
42. World Health Organization. International statistical classification of diseases and related health problems. 10th revision, version for 2007. World Health Organization/German Institute of medical documentation and information; 1994/2006; [accessed March 13, 2011]. http://www.who.int/classifications/apps/icd/icd10online/.
43. Woodward N.D., Purdon S.E., Meltzer H.Y., Zald D.H. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 2005, 8:457-472.